The STAM model as a model of liver fibrosis
Today, we present the comparison table on fibrosis models of the liver.
Liver fibrosis is defined as excessive extracellular matrix deposition preceded by chronic liver injury, which can progress to liver failure. The factors that can cause liver fibrosis include oxidative stress, cholestasis, and NASH. Therefore, when assessing the efficacy of anti-fibrotic compounds, it is necessary to use a suitable model for the target indication.
[1] Fujii et al., Med Mol Morphol. 2013
[2] Van et al., Int. J Obes. 2015.
[3] Hansen et al., Drug Discov Today. 2017
[4] Liu et al., Am J Physiol Gastrointest Liver Physiol. 2013
[5] Fickert et al., Am J Pathol. 2007
[6] Liedtke et al,. Fibrogenesis & Tissue Repair. 2013
NASH: Nonalcoholic steatohepatitis
HCC: Hepatocellular carcinoma
PSC: Primary sclerosing cholangitis
PBC: Primary biliary cirrhosis
The STAMTM model is the world’s first mouse model to show the progression of NASH to liver cancer, and was developed here, at SMC Laboratories. This model shows a pathology similar to human NASH (fatty liver → NASH → liver fibrosis → HCC). Therefore, the STAMTM model has been used in many efficacy studies, as well as in basic research, and provides a wealth of basic data. Are you interested in a drug efficacy study using the STAMTM model with high clinical correlation and the above features?
Please don’t hesitate to contact me if you would like further information on any of these models or our services.